Anbio Biotechnology (NNNN) Stock AnalysisNNNNStock AnalysisAnbio Biotechnology

Anbio Biotechnology is a Germany-based medical device company. The Company is engaged in the development of medical technology and the provision of in vitro diagnostics (IVD) products. Its products offer solutions for over the counter (OTC) use, point-of-care (POCT) settings, and laboratory applications, ensuring that both healthcare providers and patients have access to reliable and efficient diagnostic tools in any setting. Its IVD products detect a wide range of biomarkers across critical medical fields, including infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Some of its IVD platforms: Chemiluminescence Immunoassay (ChLIA), Lateral Flow Immunoassay (LFIA), Fluorescent Immunoassay (FIA), Polymerase Chain Reaction (PCR) and Loop-mediated Isothermal Amplification (LAMP). It operates in the Healthcare sector.

Anbio Biotechnology (NNNN) appears to be a good buy right now due to its strong gross margin of 92.32% projected for Q2 2025 and a significant recent price increase of 12.63% over the last 5 days. The current price is $7.67, which is well below the Fibonacci resistance levels, indicating potential upside. However, the stock has seen a year-to-date decline of 73.98%, which is a considerable risk.